# Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

> **NCT06047379** · PHASE1,PHASE2 · RECRUITING · sponsor: **Neonc Technologies, Inc.** · enrollment: 134 (estimated)

## Conditions studied

- Diffuse Astrocytoma, IDH-Mutant
- Glioblastoma, IDH-wildtype
- Brain Metastases, Adult
- Cervical Cancer
- Colorectal Cancer
- Esophageal Cancer
- Esophageal Squamous Cell Carcinoma
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Head and Neck Squamous Cell Carcinoma
- Melanoma
- Merkel Cell Carcinoma
- Microsatellite Instability-High Solid Malignant Tumor
- Mismatch Repair Deficient Solid Malignant Tumor
- Microsatellite Instability-High Colorectal Cancer
- Mismatch Repair Deficient Colorectal Cancer
- Non-small Cell Lung Cancer
- Renal Cell Carcinoma
- Small Cell Lung Cancer
- Squamous Cell Carcinoma
- Urothelial Carcinoma

## Interventions

- **DRUG:** NEO212 Oral Capsule
- **DRUG:** Ipilimumab
- **DRUG:** Pembrolizumab
- **DRUG:** Nivolumab
- **DRUG:** Regorafenib
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** FOLFIRI Protocol
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06047379
- **Lead sponsor:** Neonc Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-08-31
- **Target enrollment:** 134 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06047379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06047379, "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06047379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*